CLINICAL TRIALS PROFILE FOR ESTRADIOL; NORETHINDRONE ACETATE
✉ Email this page to a colleague
All Clinical Trials for ESTRADIOL; NORETHINDRONE ACETATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000897 ↗ | A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women. |
| NCT00229996 ↗ | Medical Treatment of Endometriosis-Associated Pelvic Pain | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 2004-07-01 | The Specific Aim of this project is to compare the efficacy and cost-effectiveness of continuous oral contraceptives versus leuprolide/norethindrone in the treatment of endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized, double-blind, trial of women with chronic pelvic pain who have been diagnosed with endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a 12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse than leuprolide/norethindrone, and that treatment with oral contraceptives is more cost-effective. |
| NCT00338052 ↗ | Study of Bleeding With Extended Administration of an Oral Contraceptive | Completed | Warner Chilcott | Phase 2 | 2006-06-01 | This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described. |
| NCT00350480 ↗ | Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial | Completed | Kaiser Permanente | N/A | 2003-04-01 | To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera) and a multidose, monophasic combination oral contraceptive in the treatment of hemodynamically stable women with non-gestational, acute uterine bleeding. |
| NCT00391807 ↗ | Study of Safety and Efficacy of an Oral Contraceptive | Completed | Warner Chilcott | Phase 3 | 2006-11-01 | This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product. |
| NCT00458458 ↗ | Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) | Unknown status | National Institutes of Health (NIH) | Phase 3 | 2004-08-01 | (A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH agonist (Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density in the two treated groups in order to demonstrate that NA does not affect bone density; (B) Minor: 1) To compare the lipid profiles of patients in the two groups to confirm the hypothesis that the effects of NA and GnRH agonists on lipid profiles are similar, 2) To determine whether quality of life, assessed by questionnaire, is better in patients assigned to NA than in patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects than GnRH agonist. |
| NCT00458458 ↗ | Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) | Unknown status | State University of New York - Downstate Medical Center | Phase 3 | 2004-08-01 | (A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH agonist (Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density in the two treated groups in order to demonstrate that NA does not affect bone density; (B) Minor: 1) To compare the lipid profiles of patients in the two groups to confirm the hypothesis that the effects of NA and GnRH agonists on lipid profiles are similar, 2) To determine whether quality of life, assessed by questionnaire, is better in patients assigned to NA than in patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects than GnRH agonist. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ESTRADIOL; NORETHINDRONE ACETATE
Condition Name
Clinical Trial Locations for ESTRADIOL; NORETHINDRONE ACETATE
Trials by Country
Clinical Trial Progress for ESTRADIOL; NORETHINDRONE ACETATE
Clinical Trial Phase
Clinical Trial Sponsors for ESTRADIOL; NORETHINDRONE ACETATE
Sponsor Name
